$1.43
2.14% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US0044461004
Symbol
ACET
Sector
Industry

Adicet Bio Inc Stock price

$1.43
+0.02 1.42% 1M
-0.90 38.63% 6M
-0.46 24.34% YTD
-0.01 0.69% 1Y
-6.36 81.64% 3Y
-59.47 97.65% 5Y
-116.73 98.79% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.03 2.14%
ISIN
US0044461004
Symbol
ACET
Sector
Industry

Key metrics

Market capitalization $115.36m
Enterprise Value $-89.58m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.97
P/B ratio (TTM) P/B ratio 0.49
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-128.09m
Free Cash Flow (TTM) Free Cash Flow $-92.58m
Cash position $224.07m
EPS (TTM) EPS $-2.53
P/E forward negative
Short interest 5.88%
Show more

Is Adicet Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Adicet Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Adicet Bio Inc forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a Adicet Bio Inc forecast:

Buy
63%
Hold
38%

Financial data from Adicet Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 7.29 7.29
3% 3%
-
-7.29 -7.29
3% 3%
-
- Selling and Administrative Expenses 13 13
7% 7%
-
- Research and Development Expense 101 101
4% 4%
-
-121 -121
4% 4%
-
- Depreciation and Amortization 7.29 7.29
3% 3%
-
EBIT (Operating Income) EBIT -128 -128
4% 4%
-
Net Profit -137 -137
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adicet Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adicet Bio Inc Stock News

Neutral
Business Wire
9 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for ...
Neutral
Business Wire
28 days ago
NORTHBROOK, Ill.--(BUSINESS WIRE)--The following is a notification from UL Solutions that the communications cable that bears the serial numbers identified below may pose a potential fire hazard. The communications cable does not comply with the appropriate Safety Standards. Name of Product: CAT 5E 350MHZ CMR MODEL NUMBER W-CAT5E/CCU/1000/W UNSHIELDED TWISTED PAIR 24 AWG/4PAIR/1000FT Remedy: UL...
Neutral
Business Wire
28 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024. Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-qualifi...
More Adicet Bio Inc News

Company Profile

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Chen Schor
Employees 143
Founded 2014
Website www.adicetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today